Drug intelligence / Profile preview

Jiangxi Univ. of Chinese Medicine butyrylcholinesterase compound 4d-13

Development stage
Preclinical
Lead developer
Jiangxi University of Traditional Chinese Medicine
01

Overview

Jiangxi Univ. of Chinese Medicine butyrylcholinesterase compound 4d-13: sourced facts only. name: "Remarkably, compound 4d-13, which demonstrated the most potent inhibitory activity against butyrylcholinesterase, also afforded consistent neuroprotective effects compared with Galantamine against the injury induced by NMDA or L-(+)-Sodium glutamate in SH-SY5Y cells." [PMID:40318509]; target: "Remarkably, compound 4d-13, which demonstrated the most potent inhibitory activity against butyrylcholinesterase, also afforded consistent neuroprotective effects compared with Galantamine against the injury induced by NMDA or L-(+)-Sodium glutamate in SH-SY5Y cells." [PMID:40318509]; developer: "Shenyang Pharmaceutical University, School of Traditional Chinese Materia Medica, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China." [PMID:40318509]; stage: "Morris water maze and step-down testing in vivo confirmed that 4d-13 could ameliorate scopolamine-induced cognitive deficits." [PMID:40318509]

02

Targets

Butyrylcholinesterase

Beyond the preview

Go deeper on Jiangxi Univ. of Chinese Medicine butyrylcholinesterase compound 4d-13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangxi Univ. of Chinese Medicine butyrylcholinesterase compound 4d-13.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call